2009 Fiscal Year Final Research Report
Development of novel glycolipids] which activate natural killer T cells to induce antitumor acivity
| Project/Area Number |
20790108
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | The Institute of Physical and Chemical Research |
|---|
Principal Investigator |
TASHIRO Takuya The Institute of Physical and Chemical Research, 免疫制御研究グループ, 研究員 (20339104)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MORI Kenji 東京大学名誉教授, 理化学研究所, 研究顧問 (20011843)
HIROKAWA Takatsugu 独立行政法人 産業技術総合研究所, 分子設計チーム (20357867)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Keywords | alpha-GalCer / CD1d / carba-galactose / cyclitol / glycosphingolipid / IFN-gamma / KRN7000 / NKT cell |
|---|
| Research Abstract |
KRN7000, an alpha-Galactosylceramide, stimulates natural killer T cells to induce antitumor activity. RCAI-56, a carba-galactose analog of KRN7000, induces a larger amount of IFN-gamma production than KRN7000. Based on the X-ray crystallographic analysis, further structure-activity relationship study was performed on RCAI-56, and it was found that RCAI-59, the 5a-deoxycyclitol analog of KRN7000, and its relatives induce potent IFN-gamma production.
|
